Biotech public markets saw a notable week as multiple companies priced IPOs, led by Eikon Therapeutics’ upsized offering. Eikon sold shares to raise roughly $381 million to advance a cancer pipeline that includes TLR7/8 co‑agonists and selective PARP programs. Other listings, including Agomab and SpyGlass, added to a pickup in public equity activity; combined proceeds from recent offerings reached the hundreds of millions. However, aftermarket trading was uneven, with some stocks slipping after initial pricing. The flurry of IPOs signals returning investor interest in select biotech subsectors, but post‑deal performance and sustained follow‑on financing will determine whether the revival broadens beyond a handful of well‑capitalized entrants.